ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1669

Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Abstract Number: 1555

Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
Abstract Number: 0169

Comparison of Diagnostic Criteria Sets in Diagnosing Antisynthetase Syndrome
Abstract Number: 0887

Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Abstract Number: 1010

Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Abstract Number: 0093

Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
Abstract Number: 0324

Comparison of NCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
Abstract Number: 1012

Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study
Abstract Number: 0398

Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Abstract Number: 0288

Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Abstract Number: 0546

COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial
Abstract Number: 2105

Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 2005

Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Abstract Number: 2259

Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
Abstract Number: 0529

Complex Relationships Between Inflammation and Clonal Hematopoiesis in Systemic Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].